PDCD1 and cancer: Combination studies with statins and immune checkpoint inhibitors, such as programmed cell death protein 1 (PD-1) inhibitors, suggest that statins may modulate the TME to enhance immune responses,55 representing a shift toward targeting cancer cell biology and tumor interactions with the immune system, which is critical in overcoming the immune evasion seen in PDAC.